[1] 国家卫生健康委员会办公厅, 国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第九版) [J]. 中国病毒病杂志,2022,0023.
[2] WHO. Therapeutics and COVID-19: living guideline[EB/OL].(2022-07-14)[2023-01-03]. https://www.who.int/publications ... herapeutics-2022.4.
[3] Singh AP, Finkelstein M, Chung M, et al. Review of Thoracic Imaging Manifestations of COVID-19 Coronaviruses and Other Pathologic [J]. Radiol Clin North Am,2022,60:359-369.
[4] CDC.Risk for COVID-19 infection, hospitalization, and death by age group [EB/OL].(2022-12-28)[2023-01-03]. https://www.cdc.gov/coronavirus/ ... -death-by-age.html.
[5] Fisman DN, Bogoch I, Lapointe-Shaw L, et al. Risk factors associated with mortality among residents with coronavirus disease 2019 (COVID-19) in long-term care facilities in Ontario, Canada [J]. JAMA Netw Open,2020,3:e2015957-e.
[6] Suthar AB, Wang J, Seffren V, et al. Public health impact of covid-19 vaccines in the US: observational study [J]. BMJ,2022, 377:e069317.
[7] Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance—United States, january 22–may 30, 2020 [J]. MMWR Morb Mortal Wkly Rep,2020,69:759.
[8] Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission [J]. Clin Infect Dis,2020,71:896-897.
[9] Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area [J]. JAMA,2020,323:2052-2059.
[10] Goldman JD, Robinson PC, Uldrick TS, et al. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies [J]. J Immunother Cancer,2021,9:e002630.
[11] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China [J]. JAMA,2020,323:1061-1069.
[12] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [J]. Lancet,2020,395:1054-1062.
[13] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J]. Lancet,2020,395:507-513.
[14] Rubin GD, Ryerson CJ, Haramati LB, et al. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner Society [J]. Radiology,2020,296:172-180.
[15] NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [R]. National Institutes of Health (US) [EB/OL].(2022-12-06)[2023-01-03]. https://www.ncbi.nlm.nih.gov/books/NBK570371/
[16] Bradley MC, Perez-Vilar S, Chillarige Y, et al. Systemic Corticosteroid Use for COVID-19 in US Outpatient Settings From April 2020 to August 2021 [J]. JAMA,2022,327:2015-2018.
[17] EUA H O E U A. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Evusheld™(Tixagevimab Co-Packaged with Cilgavimab) [EB/OL].(2022-12)[2023-01-03].https://www.fda.gov/media/154701/download.
[18] CDC. Underlying medical conditions associated with high risk for severe COVID-19: Information for healthcare providers [EB/OL].(2022-12-05)[2023-01-03].https://www.cdc.gov/coronavirus/ ... yingconditions.html
[19] Hiremath S, McGuinty M, Argyropoulos C, et al. Prescribing nirmatrelvir/ritonavir for COVID-19 in advanced CKD [J]. Clin J Am Soc Nephrol,2022,17:1247-1250.
[20] 辉瑞公司. PAXLOVID（奈玛特韦/利托那韦）—经肠内饲管给药 [Z]. 2022.
[21] 卫生健康委办公厅 中医药局办公室. 关于将阿兹夫定片纳入新型冠状病毒肺炎诊疗方案的通知 [EB/OL].(2022-08-09)[2023-01-03]. http://www.gov.cn/zhengce/zhengc ... ontent_5704788.htm.
[22] Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19 [J]. BMJ, 2020, 370 :n2219.
[23] Chu VT, Schwartz NG, Donnelly MAP, et al. Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course of SARS-CoV-2 Infection [J]. JAMA Intern Med,2022,182:701-709.
[24] White H, McDonald SJ, Barber B, et al. Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce [J]. Med J Aust,2022,217: 368-378.
[25] Mohammadi M, Khafaee Pour Khamseh A, Varpaei HA. Invasive Airway "Intubation" in COVID-19 Patients; Statistics, Causes, and Recommendations: A Review Article [J]. Anesth Pain Med,2021,11:e115868.
[26] El-Boghdadly K, Wong DJN, Owen R, et al. Risks to healthcare workers following tracheal intubation of patients with COVID-19: a prospective international multicentre cohort study [J]. Anaesthesia,2020,75:1437-1447.
[27] Camous L, Pommier JD, Martino F, et al. Very late intubation in COVID-19 patients: a forgotten prognosis factor? [J]. Crit Care,2022,26:1-4.
[28] Ospina-Tascon GA, Calderón-Tapia LE, Garcia AF, et al. Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: a randomized clinical trial [J]. JAMA,2021,326:2161-2171.
[29] Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure [J]. N Engl J Med,2015,372:2185-2196.
[30] Bellani G, Laffey JG, Pham T, et al. Noninvasive ventilation of patients with acute respiratory distress syndrome. Insights from the LUNG SAFE study [J]. Am J Respir Crit Care Med,2017,195:67-77.
[31] Ding L, Wang L, Ma W, et al. Efficacy and safety of early prone positioning combined with HFNC or NIV in moderate to severe ARDS: a multi-center prospective cohort study [J]. Crit Care,2020,24:1-8.
[32] Thompson AE, Ranard BL, Wei Y, et al. Prone positioning in awake, nonintubated patients with COVID-19 hypoxemic respiratory failure [J]. JAMA Intern Med,2020,180:1537-1539.
[33] Weiss TT, Cerda F, Scott JB, et al. Prone positioning for patients intubated for severe acute respiratory distress syndrome (ARDS) secondary to COVID-19: a retrospective observational cohort study [J]. Br J Anaesth,2021,126:48-55.
[34] Horby P, Lim WS, Emberson J R, et al. Dexamethasone in Hospitalized Patients with Covid-19 [J]. N Engl J Med,2021,384:693-704.
[35] NHS. Interleukin-6 inhibitors (tocilizumab or sarilumab) for hospitalised patients with COVID-19 pneumonia (adults) [EB/OL].(2021-02-17)[2023-01-03].file:///C:/Users/Administrator/Desktop/CEM_CMO_2021_006.pdf.
[36] Kramer A, Prinz C, Fichtner F, et al. Janus kinase inhibitors for the treatment of COVID‐19 [J]. Cochrane Database Syst Rev,2022, 6:CD015209.
[37] Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 [J]. N Engl J Med,2021,384:1491-1502.
[38] Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials [J]. Arthritis Res Ther,2011,13:1-13.
[39] Guimarães PO, Quirk D, Furtado RH, et al. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia [J]. N Engl J Med,2021,385:406-415.
[40] Han MK, Antila M, Ficker JH, et al. Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Rheumatol,2022,4:e351-e361.
[41] Lansbury L, Lim B, Baskaran V, et al. Co-infections in people with COVID-19: a systematic review and meta-analysis [J]. J Infect,2020,81:266-275.
[42] Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 [J]. J Thromb Haemost,2020,18:1023-1026.
[43] Sullivan DJ, Gebo KA, Shoham S, et al. Early Outpatient Treatment for Covid-19 with Convalescent Plasma [J]. N Engl J Med,2022,386:1700-1711.
[44] Nates JL, Nunnally M, Kleinpell R, et al. ICU Admission, Discharge, and Triage Guidelines: A Framework to Enhance Clinical Operations, Development of Institutional Policies, and Further Research [J]. Crit Care Med,2016,44:1553-1602.
[45] Poon LC, Yang H, Dumont S, et al. ISUOG Interim Guidance on coronavirus disease 2019 (COVID‐19) during pregnancy and puerperium: information for healthcare professionals–an update [J]. Ultrasound Obstet Gynecol,2020,55:848.
[46] Pfizer Lab. Fact sheet for healthcare providers: emergency use authorization for paxlovid [EB/OL].(2022-03-18)[2023-01-03].https://www.fda.gov/media/155050/download.
[47] McCreary EK, Lemon L, Megli C, et al. Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy: A Cohort Study [J]. Ann Intern Med,2022,175:1707-1715.
[48] Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis [J]. Nat Struct Mol Biol,2021,28:740-746.
[49] CDC. Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic [EB/OL].(2022-09-23)[2023-01-03]. https://www.cdc.gov/coronavirus/ ... commendations.html.
[50] Zhang M, Zheng H, Wang J. Strategy of using personal protective equipment during aerosol generating medical procedures with COVID-19 [J]. J Clin Anesth,2020,66:109911.
[51] Hong K, Cao W, Liu Z, et al. Prolonged presence of viral nucleic acid in clinically recovered COVID-19 patients was not associated with effective infectiousness [J]. Emerg Microbes Infect,2020,9:2315-2321.
[52] Kim MC, Cui C, Shin KR, et al. Duration of culturable SARS-CoV-2 in hospitalized patients with Covid-19 [J]. N Engl J Med,2021,384:671-673.
[53] Yahav D, Yelin D, Eckerle I, et al. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity [J]. Clin Microbiol Infect,2021,27:315-318.
[54] Abu-Raddad LJ, Chemaitelly H, Bertollini R. Severity of SARS-CoV-2 reinfections as compared with primary infections [J]. N Engl J Med,2021,385:2487-2489.
[55] CDC. Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates [EB/OL].(2022-12-09)[2023-01-03]. https://www.cdc.gov/vaccines/cov ... s-us-appendix.html.
[56] CDC. Ending Isolation and Precautions for People with COVID-19: Interim Guidance [EB/OL].(2022-08-31)[2023-01-03]. https://www.cdc.gov/coronavirus/ ... ion-isolation.html.
|关于我们|业务合作|手机版|新青年麻醉论坛
( 浙ICP备19050841号-1 )
发表于 2023-1-17 20:03:15
QQ好友和群
收藏
淘帖
鲜花
鸡蛋
提升卡
置顶卡
变色卡
